What is HC Wainwright's Forecast for LENZ Q1 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for LENZ Therapeutics in a research report issued on Thursday, March 20th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.52) per share for the quarter. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics' Q3 2025 earnings at ($0.73) EPS.

LENZ has been the topic of several other research reports. TD Cowen initiated coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 target price on the stock. Citigroup lifted their price objective on LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, LENZ Therapeutics presently has an average rating of "Buy" and an average price target of $41.67.

LENZ Therapeutics Stock Down 0.9 %

NASDAQ:LENZ traded down $0.23 during midday trading on Friday, reaching $26.43. The stock had a trading volume of 224,428 shares, compared to its average volume of 166,744. The stock has a market cap of $726.85 million, a P/E ratio of -5.54 and a beta of 0.58. The firm has a fifty day simple moving average of $24.22 and a two-hundred day simple moving average of $27.10. LENZ Therapeutics has a 12-month low of $14.42 and a 12-month high of $38.93.

Remove Ads

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04).

Hedge Funds Weigh In On LENZ Therapeutics

Several hedge funds have recently bought and sold shares of LENZ. Harbor Capital Advisors Inc. acquired a new position in shares of LENZ Therapeutics during the 4th quarter worth $1,270,000. Parkman Healthcare Partners LLC purchased a new position in LENZ Therapeutics during the 3rd quarter valued at about $3,308,000. Barclays PLC raised its position in LENZ Therapeutics by 273.1% during the third quarter. Barclays PLC now owns 16,463 shares of the company's stock worth $391,000 after acquiring an additional 12,051 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of LENZ Therapeutics in the third quarter valued at about $743,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of LENZ Therapeutics by 197.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock valued at $2,929,000 after purchasing an additional 81,901 shares during the last quarter. 54.32% of the stock is owned by hedge funds and other institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.